HUTCHMED Starts Phase Ia Trial of HMPL-A830 in Advanced Solid Tumors

• HUTCHMED closed its HMPL-A830 license agreement with GSK, granting worldwide rights excluding mainland China, Hong Kong, Macau and Taiwan.
• The deal provides USD 110 million upfront, up to USD 1.19 billion in milestone payments and tiered royalties on annual net sales.
• A Phase Ia trial began in China and the U.S. in September 2026, enrolling patients with advanced solid tumors.
• The experimental therapy targets EGFR-expressing tumors with a KRAS inhibitor, aiming to improve efficacy, durability and tolerability.
• HUTCHMED’s subsidiary will handle global Phase I development; GSK’s subsidiary will lead subsequent clinical development and commercialization in its licensed territory.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. HUTCHMED (China) Ltd. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202610202000PRIMZONEFULLFEED9849654) on October 21, 2026, and is solely responsible for the information contained therein.